References: Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L
BMC Immunol (2012) 13:2
You said it very elegantly
Short non-diabetic data support remaining at 2.5 mg when weight and insulin-resistance markers are already moving and tolerability favors a hold. The label still positions 2.5 mg as the starter before 5 mg, so it is a defensible low-dose floor for selected users rather than a replacement for the 5 mg obesity-trial floor
Also to aid MNOs in end-to-end testing, services quality and user experience monitoring, the Automated Testing Tool is an ideal solution
Small sample sizes can make drugs look much more or less effective than what they really are